#chemotherapy #lungcancer #immunotherapy #radiotherapy
Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study
J Thorac Oncol. 2022 Oct 25;S1556-0864(22)01853-6. doi: 10.1016/j.jtho.2022.10.003. Online ahead of print.
